News

Gene therapy AB-1005 found safe in Phase 1b Parkinson’s trial

Treatment with AB-1005 (AAV2-GDNF), AskBio’s investigational gene therapy, was safe and well tolerated among patients with mild to moderate Parkinson’s disease, according to top-line results from a Phase 1b clinical trial. The company, wholly owned by Bayer, has also completed an 18-month data collection which demonstrated the…

Cure Parkinson’s Richard Wyse honored by King Charles

Richard Wyse, MD, director of clinical development at Cure Parkinson’s, is among those in the United Kingdom (U.K.) recognized for their services to the public through inclusion on His Majesty The King’s New Year’s Honours List. Wyse, recognized for his work with Parkinson’s disease, is among…

IPX203 shows sustained safety, efficacy in RISE-PD extension trial

Using IPX203, an extended-release formulation of carbidopa/levodopa (CD/LD), was associated with a sustained control of symptoms for Parkinson’s disease patients who participated in the open-label extension of the RISE-PD Phase 3 trial. Final results from the nine-month extension study (NCT03877510) indicate dose adjustments and side effects were…

Top 10 Parkinson’s stories of 2023

Throughout 2023, we at Parkinson’s News Today brought you coverage of the latest scientific advances and developments in treatments for Parkinson’s disease. Here we’ve compiled a list of the top 10 most-read stories published this past year. We look forward to continuing to share more developments with you in…

Study finds pain to be common in early-onset Parkinson’s

More than three-quarters of people with early-onset Parkinson’s disease (EOPD) experience pain, according to a recent study conducted in Vietnam, with more severe pain reported by older patients and those with nonmotor symptoms such as depression, sexual dysfunction, and hallucinations. Additional studies with well-validated tools are needed to further…